Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the preferred regimen for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced or metastatic breast cancer. However, the optimal treatment sequencing for CDK4/6i with other availabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Melody, Hanson, Kent A., Zhang, Yixie, Zhou, Anna, Cha-Silva, Ashley S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191980/
https://www.ncbi.nlm.nih.gov/pubmed/37074594
http://dx.doi.org/10.1007/s11523-023-00957-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191980/
https://www.ncbi.nlm.nih.gov/pubmed/37074594
http://dx.doi.org/10.1007/s11523-023-00957-7

Ejemplares similares